Kadcyla (ado-trastuzumab emtansine) 부작용, 상호 작용, 용도 및 약물 상표 - 건강 2026

Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1) | OncLive

HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer | OncLive

Kadcyla (ado-trastuzumab emtansine) παρενέργειες, αλληλεπιδράσεις, χρήσεις και αποτύπωμα φαρμάκων - Υγεία 2026

LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2 ) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05 | OncLive

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03 | OncLive

HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer | OncLive

FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer: Trastuzumab Deruxtecan (T-DXd)